Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Stroke

Dabigatran is a cost-effective first-line therapy in AF

Nature Reviews Cardiology volume 9, page 312 (2012)Cite this article

Subjects

An economic analysis performed in the UK has indicated that dabigatran etexilate is likely to be a cost-effective first-line treatment for the prevention of stroke and systemic embolism in patients with atrial fibrillation. For patients aged <80 years, incremental cost-effectiveness ratios for dabigatran were £4,831 per quality-adjusted life year (QALY) gained compared with warfarin and £3,457 per QALY gained compared with aspirin. In patients aged ≥80 years, the incremental cost-effectiveness ratio for dabigatran was £7,090 per QALY gained when compared with warfarin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Kansal, A. R. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98, 573–578 (2012)

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dabigatran is a cost-effective first-line therapy in AF. Nat Rev Cardiol 9, 312 (2012). https://doi.org/10.1038/nrcardio.2012.48

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.48

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing